You are here: Industry Insights > vertex

News List

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain drugs
July 23, 2021
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548 .
Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise pharmatimes
June 16, 2021
New data presented at the European Hematology Association 2021 (EHA) virtual congress shows patients treated with Vertex/CRISPR Therapeutics’ blood disorder gene therapy CTX001 had ‘sustained response[s]’ to treatment’.
Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations drugs
June 10, 2021
Vertex Pharmaceuticals Incorporated today announced the FDA approved expanded use of Trikafta to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance
EMA, MHRA to review Vertex' Kaftrio for children with CF pharmatimes
May 21, 2021
The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated Vertex' applications to expand the scope of its cystic fibrosis (CF) treatment Kaftrio (ivacaftor/tezacaftor/elexacaftor).
MHRA approves label extension for Vertex’s Kaftrio combo pharmatimes
May 12, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a label extension for Vertex’s cystic fibrosis (CF) treatment Kaftrio in combination with ivacaftor.
Triple combo cystic fibrosis therapy Kaftrio scores EU label expansion pharmatimes
April 30, 2021
The European Commission (EC) has approved a label extension for Vertex’s triple combination cystic fibrosis (CF) treatment Kaftrio, extending its use for the ‘majority’ of patients aged 12 years and older in Europe.
EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001 pharmatimes
April 29, 2021
Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy CTX001 has been granted a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA).
Vertex and Obsidian partner to discover gene-editing medicines pharmaceutical-business-review
April 25, 2021
Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing.
Australian TGA approves Vertex’s Trikafta for cystic fibrosis treatment pharmaceutical-technology
March 26, 2021
The Australian Therapeutic Goods Administration (TGA) has approved the use of Vertex Pharmaceutical’s Trikafta (elexacaftor, tezacaftor, ivacaftor and ivacaftor) for people with cystic fibrosis (CF) aged 12 years and above.
Vertex’s Kalydeco scores another label extension in EU pharmatimes
November 09, 2020
Vertex has scored approval from the European Commission to extend the label for Kalydeco (ivacaftor) to include the treatment o infants with cystic fibrosis (CF) aged four months or older.

Previous page 1 2 3 4 5 6 7 Next page